Navigation Links
AML Therapeutics Market in the 6MM Worth $430.7m in 2017 Says a New Research Report Available at ReportsnReports.com
Date:8/15/2013

gies, and clinical trial design for the AML therapeutics market; Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline drugs. An interactive clinical and commercial analyzer tool is available and an analysis of the current and future market competition in the global AML therapeutics market along with insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Buy a copy of this report at http://www.reportsnreports.com/Purchase.aspx?name=267301 .

Key questions that this report will help you answer:

  •     Which AML patients have the greatest unmet needs?
  •     What are the R&D strategies drug makers are pursuing in the AML space?
  •     Why has it been so difficult for Pharma to develop successful therapies for AML?
  •     How are players aiming to circumvent difficulties that have historically plagued AML drug development?
  •     What are the most promising pipeline agents for AML? How do their clinical and commercial attributes compare to one another?
  •     What opportunities will remain following the launch of these pipeline agents?
  •     Do KOLs see a role for targeted therapies and immunotherapies in the treatment of AML?

Comprehensive Table of Contents with 59 data Tables and 17 Figures for the report “OpportunityAnalyzer: Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2017” can be accessed at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
2. Nile Therapeutics Reports 2011 Third Quarter Financial Results
3. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
4. Fate Therapeutics Strengthens Its iPSC Platform
5. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
6. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
7. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
8. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
9. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
10. Aratana Therapeutics Completes $15 Million Series B Financing
11. MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Francisco, CA (PRWEB) July 24, 2014 ... http://www.draperuniversity.com , is proud to announce that ... from 17 different countries will converge on the ... Valley for an intensive, experiential program focused on ... The highly selective school, currently running its sixth ...
(Date:7/24/2014)... As part of the long-term strategic approach, ... region during 2014 with potential global expansion. , "We ... DZS to manage our clinical trials globally and in ... R&D and President of SBI pharmaceuticals MENA, Dr. Riyadh ... a focus on utilizing eClinical software and flexible team ...
(Date:7/23/2014)... Al Khaimah, United Arab Emirates (UAE) (PRWEB) July 23, ... firm Grace Century recently announced that its ... Dr. Jim Vaught , Ph.D. to its growing Advisory ... said, “We are very pleased to have Dr. Vaught ... with the scientific depth and expertise that Provia’s management ...
(Date:7/23/2014)... Physicists Sergei Filippov (MIPT and Russian Quantum Center ... Brno, Czech Republic, and the Institute of Physics ... preserve quantum entanglement of particles passing through an ... long distances. Details are provided in an article ... (see preprint). , Quantum entangled particles are ...
Breaking Biology Technology:Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 2Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 3SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services 2Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 2Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 3Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 4Scientists find way to maintain quantum entanglement in amplified signals 2Scientists find way to maintain quantum entanglement in amplified signals 3Scientists find way to maintain quantum entanglement in amplified signals 4
... enhances Microsoft Amalga Life Sciences to accelerate basic research ... June 1 Microsoft Corp. today announced that it ... to acquire certain assets of Rosetta Biosoftware, a business ... of Merck & Co. Inc. The deal allows Microsoft ...
... Move strengthens Kendle,s position as a global clinical ... , CINCINNATI, June 1 Kendle (Nasdaq: ... research organization, today announced the opening of offices ... Philippines. The new operations provide Kendle,s global ...
... , ADHD symptom control demonstrated from the first time ... , PHILADELPHIA, June 1 Shire ... global specialty biopharmaceutical company, today announced that the US ... to the prescribing information for its once-daily Attention Deficit ...
Cached Biology Technology:Microsoft Signs Agreement With Merck & Co. Inc. to Acquire Assets of Rosetta Biosoftware, Strengthening Position in Life Sciences Industry 2Microsoft Signs Agreement With Merck & Co. Inc. to Acquire Assets of Rosetta Biosoftware, Strengthening Position in Life Sciences Industry 3Kendle Expands Asia/Pacific Operations with Opening of Offices in Kuala Lumpur, Bangkok and Manila 2Kendle Expands Asia/Pacific Operations with Opening of Offices in Kuala Lumpur, Bangkok and Manila 3FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 2FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 3FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 4FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 5FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 6FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 7
(Date:7/24/2014)... soup in which life arose have been maintained in our ... Anglia. , Research published today in the Journal of ... very likely also in animals still perform ancient reactions thought ... some four billion years ago. , The primordial soup theory ... a result of the combination of metals, gases from the ...
(Date:7/24/2014)... in German . ... asthma sufferers worldwide, a further 600 million people living ... global population contending with allergic rhinitis (allergic inflammation of ... other organs and parts of the body beyond the ... the form of inflammatory bowel diseases such as colitis ...
(Date:7/24/2014)... doctors and scientists from Singapore have developed Asia,s first ... eye disease that affects the cornea called corneal stromal ... vision. , Called the POLARIS TGFBI (Transforming Growth ... to aid in the diagnosis and management of patients ... members carrying a TGFBI mutation who may also be ...
Breaking Biology News(10 mins):New drugs to combat asthma and the like 2New drugs to combat asthma and the like 3Singapore team develops Asia's first genetic test that can prevent corneal blindness 2Singapore team develops Asia's first genetic test that can prevent corneal blindness 3
... leaf has revealed the oldest known evidence of a macabre ... to turn them into zombies. The discovery has been ... Hughes, from the University of Exeter, who studies parasites that ... manner of animals are susceptible to the often deadly body ...
... from Mount Sinai School of Medicine have enhanced our ... conversion, the process in which food is converted into ... scientists gain atomic-level insight into how organisms synthesize their ... published in the August issue of PLoS Biology ...
... Mont. -- Researchers at Montana State University have ... for treating antibiotic resistant infections, fungal infections and viral ... to study such compounds. The technologies are ... The first technology involves an existing clinical drug ...
Cached Biology News:Fossil reveals 48-million-year history of zombie ants 2Mount Sinai researchers discover new mechanism behind cellular energy conversion 2Montana State University offers 6 new biomedical technologies for licensing 2Montana State University offers 6 new biomedical technologies for licensing 3Montana State University offers 6 new biomedical technologies for licensing 4
delta-like 1 homolog (Drosophila)...
ELISpot kit for human Granzyme B. Kits contain PVDF plates, capture & detection antibodies, streptavidin-ALP, BSA, Skimmed dry milk, BCIP/NTB substrate, and wash buffer...
SHEEP ANTI ECHIS OCCELATUS (VENOM)...
MOUSE ANTI RAT KAPPA/LAMBDA:HRP Immunogen: MARK-1: Rat kappa light chains (IR202 and IR968)MARL-15: Rat lambda light chains (RH58, IR31)...
Biology Products: